A Study to Review the Safety of Familial Adenomatous Polyposis/Erlotinib Study


About this study

The purpose of this study is to review clinical endoscopy reports, pathology reports, and other medical records related to standard-of-care endoscopic evaluations for all participants in the parent study, MAY2016-07-01, who provide consent for the review of their medical records.  There have been reports of rapid progression of recurrent polyps after completion intervention and follow up under the parent protocol.  A review of literature found insufficient data to determine whether or not there is a longer term safety risk to the participant in MAY2016-07-01. 


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • MAY2016-07-01 participants for whom medical records are available and accessible.

Exclusion Criteria: 

  • MAY2016-07-01 participants for whom consent to review medical records cannot be obtained or documented.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Niloy Jewel Samadder, M.D.

Closed for enrollment

Contact information:

Lori Bergstrom R.N.

(507) 538-1887


More information


Publications are currently not available

Mayo Clinic Footer